Ocugen, Inc. — Director's Dealing 2018

Jun 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2018-06-15

Reporting Person: Baltzell Joshua J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-15	Stock Option (Right to Buy)	$2.97	A	25000	Acquired	2028-06-14	Common Stock (25000)	Direct

Footnotes

F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.